Holen Sie sich die Stockscreener-App
53.61
1.00%
-0.54
Handel nachbörslich:
53.61
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
ANAB|AnaptysBio Inc|Price:54.586|Chg%:+0.436 - TradingKey
AnaptysBio Inc (ANAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
First Light Asset Management LLC Decreases Stock Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
TradingKey - TradingKey
AnaptysBio Inc (ANAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ANAB|AnaptysBio Inc|Price:54.150|Chg%:-0.760 - TradingKey
AnaptysBio, Inc. $ANAB Shares Sold by Granahan Investment Management LLC - MarketBeat
Anaptysbio, Inc Net Worth (2026) - GuruFocus
Affinity Asset Advisors LLC Boosts Position in AnaptysBio, Inc. $ANAB - MarketBeat
Hsbc Holdings PLC Buys New Shares in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AnaptysBio (NASDAQ:ANAB) Trading Up 5.6%Here's What Happened - MarketBeat
Barclays Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
AnaptysBio Declines 2.14% as Shares Test Key Support ZoneVolatility Term Structure - dars.gov.et
AnaptysBio Q1 2026 Earnings: Significant EPS Miss as Pipeline Costs Weigh on ResultsEarnings Call Q&A - dars.gov.et
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB) - The Globe and Mail
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95 - Moomoo
AnaptysBio (NASDAQ:ANAB) Shares Down 6.2%Here's Why - MarketBeat
AnaptysBio, Inc.'s Equity Buyback announced on March 24, 2025 has expired with 3,444,079 shares, representing 11.5% for $68.63 million. - marketscreener.com
AnaptysBio (NASDAQ:ANAB) Trading 5.3% HigherShould You Buy? - MarketBeat
Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial? - Sahm
AnaptysBio (NASDAQ:ANAB) Shares Gap DownWhat's Next? - MarketBeat
Significant Decline for AnaptysBio (ANAB) as Shares Drop Over 10% - GuruFocus
Barclays Keeps Their Buy Rating on AnaptysBio (ANAB) - The Globe and Mail
AnaptysBio (NASDAQ:ANAB) Shares Down 7%Time to Sell? - MarketBeat
What Makes AnaptysBio (ANAB) an Investment Bet? - Yahoo Finance
Laughing Water Capital Q2 2026 Letter - Seeking Alpha
TD Cowen Remains a Buy on AnaptysBio (ANAB) - The Globe and Mail
Form 144 ANAPTYSBIO For: 13 July By Investing.com - Investing.com Australia
AnaptysBio (NASDAQ: ANAB) insider files to sell 10,694 shares after option exercise - Stock Titan
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
AnaptysBio (ANAB) Holds Near Support as Biotech Sentiment Remains CautiousCup and Handle - dars.gov.et
Is AnaptysBio (ANAB) outperforming other medical stocks this year? - MSN
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Should AnaptysBio’s (ANAB) Russell Index Removal Prompt a Rethink of Its Liquidity and Investor Base? - simplywall.st
(ANAB) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: MindWalk Holdings (HYFT), AnaptysBio (ANAB) - The Globe and Mail
UBS Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $76 - Moomoo
AnaptysBio, Inc. Financial Disclosures & Filings - TradingView
CapForce IBD 50 ETF's AnaptysBio Inc(ANAB) Holding History - GuruFocus
Form 144 ANAPTYSBIO For: 30 June By Investing.com - Investing.com Nigeria
[144] ANAPTYSBIO, INC SEC Filing - Stock Titan
AnaptysBio Is Maintained at Buy by UBS - Moomoo
Is AnaptysBio’s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus? - simplywall.st
Price to book forward of AnaptysBio, Inc. – NASDAQ:ANAB - TradingView
Enterprise value to EBITDA forward of AnaptysBio, Inc. – NASDAQ:ANAB - TradingView
Form 144 ANAPTYSBIO For: 29 June By Investing.com - Investing.com Nigeria
Form DEF 14A ANAPTYSBIO For: 29 June By Investing.com - Investing.com Nigeria
Enterprise value to revenue forward of AnaptysBio, Inc. – NASDAQ:ANAB - TradingView
ANAPTYSBIO, INC ($ANAB) CEO 2025 Pay Revealed - Quiver Quantitative
Affiliate plans to sell 9,476 ANAB shares (NASDAQ: ANAB) - Stock Titan
AnaptysBio (NASDAQ: ANAB) proxy details director votes and equity plan limits - Stock Titan
Price to earnings forward of AnaptysBio, Inc. – NASDAQ:ANAB - TradingView
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):